Abstract #0732
1 H MRS Monitoring of GABAergic and Glutamatergic Response to 4 Weeks of Antipsychotic Treatment in Medication-nave First-episode Psychosis Patients
Camilo de la Fuente-Sandoval 1 , Francisco Reyes-Madrigal 2 , Xiangling Mao 3 , Pablo Len-Ortiz 4 , Oscar Rodrguez-Mayoral 5 , Helgi Jung-Cook 6 , Ariel Graff-Guerrero 7 , Rodolfo Solis-Vivanco 8 , and Dikoma C Shungu 3
1
Neuropsychiatry & Laboratory of Experiment
Psychiatry, Instituto Nacional de Neurologa y
Neurociruga (INNN), Mexico City, Distrito Federal,
Mexico,
2
Laboratory of Experimental
Psychiatry, INNN, Mexico City, Mexico,
3
Radiology,
Weill Cornell Medical College, New York, NY, United
States,
4
Education,
INNN, Mexico City, Mexico,
5
Palliative
Care Unit, Instituto Nacional de Cancerologa, Mexico
City, Mexico,
6
Laboratory
of Neuropsychopharmacology, INNN, Mexico City, Mexico,
7
Multimodal
Neuroimaging Schizophrenia Group, Centre for Addiction
and Mental Health, Toronto, ON, Canada,
8
Laboratory
of Neuropsychology, INNN, Mexico City, Mexico
Dysregulations of GABA and glutamate are implicated in
schizophrenia pathophysiology. Using
1
H
MRS, GABA and glutamate+glutamine (Glx) levels were
measured at baseline and after 4 weeks of antipsychotic
treatment in the medial prefrontal cortex (MPFC) and
dorsal caudate (DCA) of medication-naive first-episode
psychosis (FEP) patients and matched health controls.
The results showed higher baseline levels of both GABA
and Glx in the MPFC and DCA of FEP subjects than in
controls, which normalized in both brain regions after 4
weeks of treatment. These data suggest that
schizophrenia is characterized by elevations of GABA and
Glx, which normalize with antipsychotic treatment.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
